News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
